- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01:06 | Sharp Therapeutics Corp (2): Sharp Therapeutics closes $1.55M (U.S.) note financing | 1 | Stockwatch | ||
| 00:14 | Sharp Therapeutics Corp.: Sharp Therapeutics Corp. Announces Fourth Quarter 2025 Results, Closing of Convertible Note Offering and Adoption of Semi-Annual Reporting | 373 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 17, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its annual... ► Artikel lesen | |
| SHARP THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.04. | Sharp Therapeutics Corp (2): Sharp seeks replacement compound for Gaucher, GBA1 | 1 | Stockwatch | ||
| 11.04. | Sharp Therapeutics Corp (2): Sharp closes $200k (U.S.) fourth tranche of placement | 3 | Stockwatch | ||
| 10.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs | 850 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that following longer-term... ► Artikel lesen | |
| 10.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Fourth Tranche of Unsecured Convertible Note Offering | 917 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it... ► Artikel lesen | |
| 03.04. | Sharp Therapeutics Corp (2): Sharp Therapeutics closes third tranche of offering | 1 | Stockwatch | ||
| 02.04. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering | 790 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has... ► Artikel lesen | |
| 14.03. | Sharp Therapeutics Corp (2): Sharp Therapeutics closes second tranche of placement | 2 | Stockwatch | ||
| 13.03. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering | 811 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - March 13, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it... ► Artikel lesen | |
| 28.02. | Sharp Therapeutics Corp (2): Sharp Therapeutics closes first tranche of financing | 3 | Stockwatch | ||
| 27.02. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of First Tranche of Unsecured Convertible Note Offering | 505 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that... ► Artikel lesen | |
| 03.02. | Sharp Therapeutics Corp (2): Sharp arranges $3-million (U.S.) note offering | 1 | Stockwatch | ||
| 02.02. | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes | 324 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce the terms... ► Artikel lesen | |
| 27.01. | Sharp Therapeutics Corp (2): Sharp Therapeutics appoints Ely to advisory board | 2 | Stockwatch | ||
| 27.01. | Gaucher disease expert Robin Ely joins Sharp Therapeutics advisory board | 2 | Investing.com | ||
| 19.12.25 | Sharp Therapeutics announces $10M non-brokered private placement | 2 | Seeking Alpha | ||
| 19.12.25 | Sharp Therapeutics Corp.: Sharp Therapeutics Provides Update on Non-Brokered Private Placement and Grant of Options | 590 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - December 19, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that... ► Artikel lesen | |
| 26.11.25 | Sharp Therapeutics Corp. Reports Third Quarter 2025 Results and Development Update | 369 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - November 26, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its condensed... ► Artikel lesen | |
| 14.10.25 | Sharp Therapeutics Corp.: Sharp Therapeutics Arranges Non-Brokered Private Placement | 389 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - October 14, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that it... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 11,010 | +2,42 % | Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns? | ||
| PRAXIS PRECISION MEDICINES | 342,50 | +6,72 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| QIAGEN | 35,350 | +1,00 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,250 | +2,93 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 | ||
| TREVI THERAPEUTICS | 15,210 | +4,61 % | Netflix, Trevi Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session | ||
| BIONTECH | 87,55 | +0,11 % | BioNTech-Aktie: Wann geht's wieder über 100 Euro? | BioNTech hat neue klinische Daten zu einem wichtigen Krebsmedikament veröffentlicht und damit erneut Fortschritte in seiner Onkologie-Pipeline demonstriert. Für Investoren sind solche Studiendaten entscheidend... ► Artikel lesen | |
| CG ONCOLOGY | 73,44 | +10,67 % | CG Oncology-Aktie erreicht Rekordhoch von 72,29 US-Dollar | ||
| SUMMIT THERAPEUTICS | 25,140 | +2,95 % | UBS reiterates Buy on Summit Therapeutics stock ahead of trial data | ||
| EVOTEC | 5,640 | +1,26 % | Aktien KW 15 Trump hält die Börsen im Griff. Wacklige Waffenruhe bringt Erholung, aber… News. Mutares. Evotec. TKMS. technotrans. HENSOLDT. Renk. Circus. Albis Leasing. Rheinmetall | Aktien - Erholungsaufatmer nach Waffenstillstand. Mit apokalyptischen Drohungen malte Trump die "Steinzeit" für den Iran an die Wand. Unter Vermittlung Pakistans - auch Chinas? - gab es kurz vorher... ► Artikel lesen | |
| IMMUNOVANT | 29,300 | +7,13 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| CABALETTA BIO | 3,440 | -2,27 % | Cellares' Cell Shuttle used in first patient infusions of Cabaletta Bio CAR T therapy | ||
| ERASCA | 18,995 | +4,20 % | Jefferies reiterates Erasca stock Buy rating on rival trial data | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 18,340 | +3,06 % | H.C. Wainwright reiterates Moonlake stock rating on HS potential | ||
| BEAM THERAPEUTICS | 31,385 | +3,48 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| PSYENCE BIOMEDICAL | 7,590 | +29,30 % | Psyence Biomedical Ltd.: Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine | NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin... ► Artikel lesen |
Das Unternehmen SHARP THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHARP THERAPEUTICS CORP finden Sie auf Wallstreet Online.